HUMPHREY RACHEL 4
4 · CytomX Therapeutics, Inc. · Filed Mar 5, 2018
Insider Transaction Report
Form 4
HUMPHREY RACHEL
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2018-03-02$6.61/sh+16,160$106,894→ 46,394 total - Sale
Common Stock
2018-03-02$30.00/sh−16,160$484,800→ 30,234 total - Exercise/Conversion
Stock Option (Right to Buy)
2018-03-02−16,160→ 222,980 totalExercise: $6.61Exp: 2025-08-27→ Common Stock (16,160 underlying)
Footnotes (2)
- [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- [F2]This option vests 25% on August 28, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on August 28, 2019.